ArticlePharmacoEconomics2021

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.

Yong-Jin Kim et al.PubMed ↗Publisher ↗

No numbers read from the abstract.